Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

NCT ID: NCT04502069

Last Updated: 2020-08-11

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-31
• Study Completion Date: 2021-06-30

Brief Summary

Patients diagnosed with COVID-19 infection will be offered treatment with Opaganib, 500 mg Q12 hours. Opaganib will be continuously administered for up to 2 weeks, until discharged on room air (if earlier than 2 weeks).

Detailed Description

Patients diagnosed with COVID-19 infection by nasopharyngeal viral swab, classified as severe disease, category 5, by the WHO Ordinal Scale For Clinical Improvement (who require oxygen support by high flow nasal cannula but do not require mechanical ventilation) at the time of initiation of therapy will be offered treatment with Opaganib, 500 mg Q12 hours.

Opaganib will be continuously administered for up to 2 weeks, until discharged on room air (if earlier than 2 weeks), upon voluntary withdrawal is initiated by the patient or when the physician decides that it is not in the patient's best interest to continue.

Conditions

COVID-19; Lung Infection

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open label opaganib

opaganib dosed at 500 mg Q12 hours

Group Type: EXPERIMENTAL

Opaganib

Intervention Type: DRUG

500 mg Q12 hours orally

Interventions

Opaganib

500 mg Q12 hours orally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with proven COVID-19 infection diagnosed by nasopharyngeal viral swab who require external oxygen support by high flow nasal cannulas (HFNC) but not mechanical ventilation.

2. Pneumonia documented by chest x-ray (CXR)

3. The patient or guardian must have signed a written IRB-approved informed consent.

4. A negative pregnancy test (if woman of childbearing potential).

5. Acceptable liver and renal function:

1. Bilirubin ≤ 1.5 times upper limit of normal (CTCAE Grade 2 baseline)

2. AST (SGOT), ALT (SGPT) ≤ 3.0 x upper limit of normal (ULN),

3. Serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1 baseline)

6. Acceptable hematologic status:

1. Absolute neutrophil count ≥1000 cells/mm3

2. Platelet count ≥75,000 (plt/mm3) (CTCAE Grade 1 baseline)

3. Hemoglobin ≥ 9 g/dL

7. Clinically acceptable blood sugar control if diabetic

8. EKG showing no QTc prolongation

Exclusion Criteria

1. Any co-morbidity that that is considered by the treating investigator as an unacceptable risk

2. Pregnant or nursing women

3. Unwillingness or inability to comply with procedures required in this protocol.

4. Caution must be exercised in patients who are receiving drugs that were sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes that cannot be stopped or replaced with another appropriate medication or not given for the duration of the clinical study. These patients must be discussed with the sponsor in order to determine appropriateness for opaganib therapy.

5. Patients who are taking warfarin, apixaban, argatroban or rivaroxaban

6. Patients with QTc prolongation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RedHill Biopharma Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark L Levitt, MD

Role: STUDY_DIRECTOR

RedHill Biopharma Limited

Locations

Shaare Zedek Medical Center

Jerusalem, , Israel

Countries

Israel

Other Identifiers

ABC-112

Identifier Type: -

Identifier Source: org_study_id